Jason Aldred

2.0k total citations
34 papers, 633 citations indexed

About

Jason Aldred is a scholar working on Neurology, Epidemiology and Cognitive Neuroscience. According to data from OpenAlex, Jason Aldred has authored 34 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Neurology, 7 papers in Epidemiology and 6 papers in Cognitive Neuroscience. Recurrent topics in Jason Aldred's work include Parkinson's Disease Mechanisms and Treatments (30 papers), Neurological disorders and treatments (23 papers) and Restless Legs Syndrome Research (7 papers). Jason Aldred is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (30 papers), Neurological disorders and treatments (23 papers) and Restless Legs Syndrome Research (7 papers). Jason Aldred collaborates with scholars based in United States, United Kingdom and Australia. Jason Aldred's co-authors include David G. Standaert, Esther Cubo, Meredith Spindler, Lars Bergmann, Pavnit Kukreja, К. Ray Chaudhuri, John G. Nutt, Mirosław Bryś, Andreas Weihofen and Weining Robieson and has published in prestigious journals such as Neurology, The Lancet Neurology and Movement Disorders.

In The Last Decade

Jason Aldred

29 papers receiving 623 citations

Peers

Jason Aldred
Corneliu Luca United States
Samuel Blankson Ghana
Rebecca Gilbert United States
R. De Notaris Italy
Alexandre Mendes Portugal
Danish Bhatti United States
Manuel Delgado‐Alvarado Spain
Nataliya Titova Russia
Mitsuru Shiba Japan
Gail A. Kang United States
Corneliu Luca United States
Jason Aldred
Citations per year, relative to Jason Aldred Jason Aldred (= 1×) peers Corneliu Luca

Countries citing papers authored by Jason Aldred

Since Specialization
Citations

This map shows the geographic impact of Jason Aldred's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Aldred with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Aldred more than expected).

Fields of papers citing papers by Jason Aldred

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Aldred. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Aldred. The network helps show where Jason Aldred may publish in the future.

Co-authorship network of co-authors of Jason Aldred

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Aldred. A scholar is included among the top collaborators of Jason Aldred based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Aldred. Jason Aldred is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aldred, Jason, Tove Henriksen, Martin Bouchard, et al.. (2025). Treatment patterns with long-term foslevodopa/foscarbidopa use in Parkinson’s disease. Parkinsonism & Related Disorders. 134. 107598–107598. 1 indexed citations
2.
Soileau, Michael J., Rajeev Kumar, Pavnit Kukreja, et al.. (2025). Patients’ experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson’s disease. Journal of Neurology. 272(6). 416–416. 1 indexed citations
3.
Aldred, Jason, Manon Bouchard, Juan Carlos Martínez‐Castrillo, et al.. (2025). Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease. Movement Disorders Clinical Practice. 13(1). 181–190.
4.
Aldred, Jason, Tove Henriksen, Martin Bouchard, et al.. (2024). Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson’s disease. Parkinsonism & Related Disorders. 122. 106128–106128. 1 indexed citations
5.
Kern, Drew S., Khashayar Dashtipour, Jason Aldred, et al.. (2023). Safety of Foslevodopa/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial (S32.004). Neurology. 100(17_supplement_2).
6.
Chaudhuri, К. Ray, Norbert Kovács, Francesco E. Pontieri, et al.. (2023). Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results. Journal of Parkinson s Disease. 13(5). 769–783. 21 indexed citations
7.
8.
Pahwa, Rajesh, et al.. (2022). Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial. Clinical Parkinsonism & Related Disorders. 8. 100181–100181. 1 indexed citations
9.
Pahwa, Rajesh, Jason Aldred, Yash J. Jalundhwala, et al.. (2022). Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses. Neurology and Therapy. 11(2). 711–723. 2 indexed citations
10.
Soileau, Michael J., Jason Aldred, Nahome Fisseha, et al.. (2022). Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. The Lancet Neurology. 21(12). 1099–1109. 93 indexed citations
11.
Kovács, Norbert, Lars Bergmann, Esther Cubo, et al.. (2021). Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. Repository of the Academy's Library (Library of the Hungarian Academy of Sciences). 9 indexed citations
12.
Aldred, Jason, Theresa A. Zesiewicz, Yarema Bezchlibnyk, et al.. (2021). Utilization of New Visualization Software for Deep Brain Stimulation Programming Using a Multiple-Source, Constant-Rechargeable System (1479). Neurology. 96(15_supplement). 1 indexed citations
13.
Alva, Gustavo, Jason Aldred, Bruce Coate, et al.. (2020). An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression. Journal of Parkinson s Disease. 10(4). 1751–1761. 13 indexed citations
14.
15.
Khani, Mohammad Reza, Marianne Schmid Daners, Gregory T. Carter, et al.. (2020). Non-invasive MRI quantification of cerebrospinal fluid dynamics in amyotrophic lateral sclerosis patients. Fluids and Barriers of the CNS. 17(1). 4–4. 27 indexed citations
16.
Bryś, Mirosław, Laura Fanning, Serena Hung, et al.. (2019). Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054. Movement Disorders. 34(8). 1154–1163. 139 indexed citations
17.
Carlson, Jonathan D., et al.. (2019). Deep Brain Stimulation Generator Replacement in End-Stage Parkinson Disease. World Neurosurgery. 128. e683–e687. 3 indexed citations
18.
Bryś, Mirosław, Aaron Ellenbogen, Laura Fanning, et al.. (2018). Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001). Neurology. 90(15_supplement). 17 indexed citations
19.
Burack, Michelle A., Jason Aldred, Cindy Zadikoff, et al.. (2018). Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners. Movement Disorders Clinical Practice. 5(4). 383–393. 19 indexed citations
20.
Aldred, Jason, et al.. (2012). Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Movement Disorders. 27(6). 750–753. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Corneliu Luca Breakdown of academic impact, for papers by Samuel Blankson Breakdown of academic impact, for papers by Rebecca Gilbert Breakdown of academic impact, for papers by R. De Notaris Breakdown of academic impact, for papers by Alexandre Mendes Breakdown of academic impact, for papers by Danish Bhatti Breakdown of academic impact, for papers by Manuel Delgado‐Alvarado Breakdown of academic impact, for papers by Nataliya Titova Breakdown of academic impact, for papers by Mitsuru Shiba Breakdown of academic impact, for papers by Gail A. Kang
Rankless by CCL
2026